查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046161

敗血症診斷市場－全球產業規模、佔有率、趨勢、機會、預測：按技術、產品、診斷方法、病原體、地區和競爭格局分類，2021-2031年

Sepsis Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology, By Product, By Diagnostic Method, By Pathogen, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球敗血症診斷市場預計將大幅擴張，從 2025 年的 6.5719 億美元成長到 2031 年的 10.5393 億美元，複合年成長率為 8.19%。

這一成長主要受醫療相關感染病例增加、全球老年人口不斷成長以及為降低高死亡率而迫切需要快速診斷結果等因素驅動。預計到2025年，美國因敗血症住院治療的年度費用將達到620億美元。快速分子診斷技術的進步正在透過提供快速且準確的資訊徹底改變這一領域。我們正在擺脫耗時數天的傳統血液培養方法，轉向可在不到一小時內提供結果的新型宿主反應和分子平台。例如，Inflammatix公司的TriVerity檢測系統於2025年1月獲得FDA核准，該系統可檢測29個基因，從而快速評估感染疾病和敗血症的風險。全球膿毒症發病率的上升（估計每年有2140萬人死於膿毒症）以及公眾意識的提高（到2025年9月，75%的美國成年人將了解膿毒症）進一步加劇了對可靠診斷方案的需求，並推動了市場擴張。這將有助於區分細菌感染和感染疾病，感染疾病最佳化抗生素的使用。

市場概覽
預測期 2027-2031
市場規模：2025年 6.5719億美元
市場規模：2031年 1,053,930,000 美元
複合年成長率：2026-2031年 8.19%
成長最快的細分市場 細菌性敗血症
最大的市場 北美洲

市場促進因素

快速分子診斷技術的進步正在革新全球敗血症診斷市場，滿足了臨床決策對速度和準確性的迫切需求。傳統的血液培養通常需要數天才能得出結果，而新型宿主反應和分子診斷平台現在可以在一小時內提供可操作的資訊。近期一系列監管里程碑標誌著精準醫療的轉型，這些里程碑鞏固了新一代工具的臨床效用。例如，2025年1月，Inflammatix公司的TriVerity檢測系統獲得FDA核准。該系統是一種新型分子診斷方法，透過測量29個基因的表達來快速評估感染疾病和敗血症的風險。這些創新將使臨床醫生能夠更有效地區分細菌感染和病毒感染疾病，從而減少重症監護環境中不合理使用抗生素的情況，並改善患者預後。敗血症和院內感染疾病的上升是推動市場擴張的主要動力，也因此產生了可靠診斷方案的全球性需求。人口老化和醫療干預措施日益複雜化導致敗血症盛行率激增，持續需要早期檢測能力來降低死亡率。據估計，全球每年約有2,140萬人死於敗血症相關疾病，這場日益嚴重的健康危機正促使各國進行廣泛的公共衛生工作，以提高公眾意識並加強防治。這直接影響了市場滲透率，預計到2025年9月，美國成年人對敗血症的認知度將達到創紀錄的75%，這將顯著提高醫療機構部署診斷設備的優先順序。

市場挑戰

自動化敗血症診斷系統所需的大量資本投入是市場成長的主要障礙。這些先進平台需要大量的設備安裝前期費用，以及持續的維護和專用試劑費用。因此，營運預算有限的小規模醫療機構和地區醫院往往無法承擔如此昂貴的技術，這實際上限制了高通量診斷工具的應用範圍，使其僅限於資金雄厚的大規模醫療中心，並縮小了製造商的潛在市場。這種經濟限制在發展中地區尤其嚴重，這些地區的臨床需求最高，但財政資源卻十分匱乏。先進診斷技術的高成本以及新興經濟體醫療基礎設施的不平衡是其廣泛應用的重大障礙。到2025年，全球約85%的敗血症病例將發生在低收入和中等收入國家，這些國家的醫療體系限制和診斷能力不足將繼續阻礙有效的患者照護。疾病負擔的地理集中以及自動化檢測解決方案的價格可負擔性限制了市場在具有極高銷量成長潛力的地區的擴張，而缺乏對新分子技術的充分報銷框架進一步加劇了這種情況的複雜性。

市場趨勢

人工智慧 (AI) 和機器學習在早期預測方面的應用，正將敗血症的治療模式從被動治療轉向預測性風險分層。先進的演算法模型能夠即時分析電子健康記錄，在臨床狀況惡化前數小時識別出細微的生理變化，這相比依賴終末期生命徵象的傳統評分系統具有顯著優勢。這種事先識別高風險患者的能力，使得早期介入方案得以實施，從而直接應對疾病的時間限制。研究表明，到 2025 年 5 月，引入深度學習預測工具可使院內膿毒症死亡率相對降低 17%。另一個重要趨勢是利用微流體技術實現診斷設備的微型化，從而能夠在臨床環境中快速評估宿主的免疫反應。這些平台利用微通道測量白血球的生物物理形變，可在數分鐘內提供關於免疫失調的客觀數據，有效避免了傳統培養方法漫長的等待時間。這種方法能夠實現即時精準的分診，在確保有效使用抗生素的同時，防止敗血性休克的進展。例如，使用 IntelliSep 快速敗血症診斷測試​​等微流體技術對感染疾病患者進行評估，到 2025 年 12 月，與接受標準治療的患者相比，死亡率降低了 42%。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球膿毒症診斷市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 透過技術（分子診斷、微生物學、免疫檢測和其他技術）
    • 依產品類別（儀器、檢測及試劑、其他產品）
    • 診斷方法（常規診斷、自動診斷）
    • 依病原體分類（細菌性敗血症、黴菌性敗血症、其他病原體）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美膿毒症診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲敗血症診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區敗血症診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲膿毒症診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲敗血症診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球膿毒症診斷市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Abbott Laboratories
  • DiaSorin SpA
  • Becton, Dickinson, and Company
  • BioMerieux Inc.
  • F. Hoffmann-La Roche AG
  • Danaher Corporation
  • Thermo Fisher Scientific Inc
  • Siemens Healthineers AG
  • Seegene, Inc.
  • Roche Diagnostics Corporation

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 16288

The Global Sepsis Diagnostics Market is poised for significant expansion, projected to reach USD 1053.93 Million by 2031 from USD 657.19 Million in 2025, reflecting an 8.19% CAGR. This growth is primarily fueled by the increasing prevalence of healthcare-acquired infections, the expanding global geriatric population, and the urgent demand for rapid diagnostic results to reduce high mortality rates, given sepsis accounted for an estimated $62 billion in annual US hospitalization costs in 2025. Technological advancements in rapid molecular diagnostics are revolutionizing this sector by providing swift and accurate insights, moving beyond traditional blood cultures that take days to emerging host-response and molecular platforms delivering results in under an hour; for instance, Inflammatix received FDA clearance in January 2025 for its TriVerity Test System, which measures 29 genes to rapidly assess infection and sepsis risk. The escalating global incidence of sepsis, with an estimated 21.4 million sepsis-related deaths annually, alongside rising public awareness (75% in US adults by September 2025), further intensifies the need for robust diagnostic protocols and propels market expansion, facilitating better differentiation between bacterial and viral infections and optimizing antibiotic use.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 657.19 Million
Market Size 2031USD 1053.93 Million
CAGR 2026-20318.19%
Fastest Growing SegmentBacterial Sepsis
Largest MarketNorth America

Market Driver

Technological advancements in rapid molecular diagnostics are revolutionizing the Global Sepsis Diagnostics Market by addressing the critical need for speed and accuracy in clinical decision-making. Conventional blood cultures often require days to yield results, whereas emerging host-response and molecular platforms can now provide actionable insights in under an hour. This shift towards precision medicine is exemplified by recent regulatory milestones that validate the clinical utility of these next-generation tools, such as Inflammatix receiving FDA marketing authorization in January 2025 for its TriVerity Test System, a novel molecular diagnostic that measures the expression of 29 genes to rapidly evaluate infection and sepsis risk. Such innovations enable clinicians to distinguish between bacterial and viral infections more effectively, thereby reducing inappropriate antibiotic use and improving patient outcomes in critical care settings. The rising incidence of sepsis and hospital-acquired infections acts as a primary catalyst for market expansion, necessitating robust diagnostic protocols globally. The prevalence of sepsis has surged due to an aging population and the increasing complexity of medical interventions, creating a sustained demand for early detection capabilities to mitigate mortality. With an estimated 21.4 million sepsis-related deaths globally in a single year, this growing health crisis has triggered extensive public health efforts to improve recognition and management, directly influencing market adoption, with US adult awareness of 'sepsis' reaching a record high of 75% by September 2025, significantly driving the prioritization of diagnostic procurement in healthcare facilities.

Market Challenge

The substantial capital investment required for automated sepsis diagnostic systems presents a formidable barrier to market growth. These advanced platforms necessitate significant upfront costs for instrumentation, alongside ongoing expenses for maintenance and specialized reagents. Consequently, smaller healthcare facilities and community hospitals with restricted operational budgets often cannot justify the procurement of such expensive technology, effectively limiting the adoption of high-throughput diagnostic tools to large, well-funded medical centers and narrowing the addressable market for manufacturers. This economic constraint is particularly acute in developing regions where the clinical need is highest but financial resources are scarce. The disparity between the high cost of advanced diagnostics and the available healthcare infrastructure in emerging economies creates a significant impediment to widespread implementation. Approximately 85% of global sepsis cases occurred in low- and middle-income countries in 2025, where health system constraints and limited diagnostic capacity continue to hinder effective patient care. This disconnect between the geographical concentration of disease burden and the affordability of automated testing solutions restricts market expansion in regions that offer significant volume-based growth potential, further complicated by the lack of adequate reimbursement frameworks for new molecular technologies.

Market Trends

The Integration of Artificial Intelligence and Machine Learning for Early Prediction is shifting sepsis management from reactive treatment to predictive risk stratification. Advanced algorithmic models now analyze electronic health records in real-time to identify subtle physiological patterns hours before clinical deterioration, offering a significant advantage over traditional scoring systems that rely on late-stage vital signs. This capability to preemptively flag high-risk patients allows for earlier intervention bundles, directly addressing the time-sensitive nature of the condition; the implementation of a deep learning prediction tool was associated with a 17% relative decrease in in-hospital sepsis mortality by May 2025. Another key trend is the Miniaturization of Diagnostic Devices Using Microfluidic Technology, which enables the rapid assessment of host immune responses directly at the point of care. By leveraging micro-channels to measure the biophysical deformation of white blood cells, these platforms provide objective data on immune dysregulation in minutes, effectively bypassing the prolonged wait times associated with culture-based methods. This approach facilitates immediate, precision-guided triage, ensuring that antibiotics are administered effectively while preventing the progression of septic shock; for example, patients with suspected infection evaluated using microfluidic technology like the IntelliSep rapid sepsis diagnostic test had a 42% lower mortality rate compared to those receiving standard care by December 2025.

Key Market Players

  • Abbott Laboratories
  • DiaSorin SpA
  • Becton, Dickinson, and Company
  • BioMerieux Inc.
  • F. Hoffmann-La Roche AG
  • Danaher Corporation
  • Thermo Fisher Scientific Inc
  • Siemens Healthineers AG
  • Seegene, Inc.
  • Roche Diagnostics Corporation

Report Scope

In this report, the Global Sepsis Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Sepsis Diagnostics Market, By Technology

  • Molecular Diagnostics
  • Microbiology
  • Immunoassay
  • Other Technologies

Sepsis Diagnostics Market, By Product

  • Instruments
  • Assays and Reagents
  • Other Products

Sepsis Diagnostics Market, By Diagnostic Method

  • Conventional Diagnostics
  • Automated Diagnostics

Sepsis Diagnostics Market, By Pathogen

  • Bacterial Sepsis
  • Fungal Sepsis
  • Other Pathogens

Sepsis Diagnostics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Sepsis Diagnostics Market.

Available Customizations:

Global Sepsis Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Sepsis Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Technology (Molecular Diagnostics, Microbiology, Immunoassay, Other Technologies)
    • 5.2.2. By Product (Instruments, Assays and Reagents, Other Products)
    • 5.2.3. By Diagnostic Method (Conventional Diagnostics, Automated Diagnostics)
    • 5.2.4. By Pathogen (Bacterial Sepsis, Fungal Sepsis, Other Pathogens)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Sepsis Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Technology
    • 6.2.2. By Product
    • 6.2.3. By Diagnostic Method
    • 6.2.4. By Pathogen
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Sepsis Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Technology
        • 6.3.1.2.2. By Product
        • 6.3.1.2.3. By Diagnostic Method
        • 6.3.1.2.4. By Pathogen
    • 6.3.2. Canada Sepsis Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Technology
        • 6.3.2.2.2. By Product
        • 6.3.2.2.3. By Diagnostic Method
        • 6.3.2.2.4. By Pathogen
    • 6.3.3. Mexico Sepsis Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Technology
        • 6.3.3.2.2. By Product
        • 6.3.3.2.3. By Diagnostic Method
        • 6.3.3.2.4. By Pathogen

7. Europe Sepsis Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Technology
    • 7.2.2. By Product
    • 7.2.3. By Diagnostic Method
    • 7.2.4. By Pathogen
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Sepsis Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Technology
        • 7.3.1.2.2. By Product
        • 7.3.1.2.3. By Diagnostic Method
        • 7.3.1.2.4. By Pathogen
    • 7.3.2. France Sepsis Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Technology
        • 7.3.2.2.2. By Product
        • 7.3.2.2.3. By Diagnostic Method
        • 7.3.2.2.4. By Pathogen
    • 7.3.3. United Kingdom Sepsis Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Technology
        • 7.3.3.2.2. By Product
        • 7.3.3.2.3. By Diagnostic Method
        • 7.3.3.2.4. By Pathogen
    • 7.3.4. Italy Sepsis Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Technology
        • 7.3.4.2.2. By Product
        • 7.3.4.2.3. By Diagnostic Method
        • 7.3.4.2.4. By Pathogen
    • 7.3.5. Spain Sepsis Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Technology
        • 7.3.5.2.2. By Product
        • 7.3.5.2.3. By Diagnostic Method
        • 7.3.5.2.4. By Pathogen

8. Asia Pacific Sepsis Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Technology
    • 8.2.2. By Product
    • 8.2.3. By Diagnostic Method
    • 8.2.4. By Pathogen
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Sepsis Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Technology
        • 8.3.1.2.2. By Product
        • 8.3.1.2.3. By Diagnostic Method
        • 8.3.1.2.4. By Pathogen
    • 8.3.2. India Sepsis Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Technology
        • 8.3.2.2.2. By Product
        • 8.3.2.2.3. By Diagnostic Method
        • 8.3.2.2.4. By Pathogen
    • 8.3.3. Japan Sepsis Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Technology
        • 8.3.3.2.2. By Product
        • 8.3.3.2.3. By Diagnostic Method
        • 8.3.3.2.4. By Pathogen
    • 8.3.4. South Korea Sepsis Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Technology
        • 8.3.4.2.2. By Product
        • 8.3.4.2.3. By Diagnostic Method
        • 8.3.4.2.4. By Pathogen
    • 8.3.5. Australia Sepsis Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Technology
        • 8.3.5.2.2. By Product
        • 8.3.5.2.3. By Diagnostic Method
        • 8.3.5.2.4. By Pathogen

9. Middle East & Africa Sepsis Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Technology
    • 9.2.2. By Product
    • 9.2.3. By Diagnostic Method
    • 9.2.4. By Pathogen
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Sepsis Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Technology
        • 9.3.1.2.2. By Product
        • 9.3.1.2.3. By Diagnostic Method
        • 9.3.1.2.4. By Pathogen
    • 9.3.2. UAE Sepsis Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Technology
        • 9.3.2.2.2. By Product
        • 9.3.2.2.3. By Diagnostic Method
        • 9.3.2.2.4. By Pathogen
    • 9.3.3. South Africa Sepsis Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Technology
        • 9.3.3.2.2. By Product
        • 9.3.3.2.3. By Diagnostic Method
        • 9.3.3.2.4. By Pathogen

10. South America Sepsis Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Technology
    • 10.2.2. By Product
    • 10.2.3. By Diagnostic Method
    • 10.2.4. By Pathogen
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Sepsis Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Technology
        • 10.3.1.2.2. By Product
        • 10.3.1.2.3. By Diagnostic Method
        • 10.3.1.2.4. By Pathogen
    • 10.3.2. Colombia Sepsis Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Technology
        • 10.3.2.2.2. By Product
        • 10.3.2.2.3. By Diagnostic Method
        • 10.3.2.2.4. By Pathogen
    • 10.3.3. Argentina Sepsis Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Technology
        • 10.3.3.2.2. By Product
        • 10.3.3.2.3. By Diagnostic Method
        • 10.3.3.2.4. By Pathogen

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Sepsis Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Abbott Laboratories
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. DiaSorin SpA
  • 15.3. Becton, Dickinson, and Company
  • 15.4. BioMerieux Inc.
  • 15.5. F. Hoffmann-La Roche AG
  • 15.6. Danaher Corporation
  • 15.7. Thermo Fisher Scientific Inc
  • 15.8. Siemens Healthineers AG
  • 15.9. Seegene, Inc.
  • 15.10. Roche Diagnostics Corporation

16. Strategic Recommendations

17. About Us & Disclaimer